No Data
Focus on Amano and Tirado [Today's Individual Stock Trends]
In the U.S. stock market on the 21st, the Dow Jones Industrial Average dropped by 971.82 points to 38,170.41, the Nasdaq Composite Index fell by 415.55 points to 15,870.90, and the Chicago Nikkei 225 Futures decreased by 105 yen from the day in Osaka to 34,155 yen. The exchange rate is 1 dollar = 140.80-90 yen. In today's Tokyo market, Amano <6436> revised up its earnings and Dividends forecast for the fiscal year ending March 2025, Tsubaki <7236> revised up its earnings forecast for the same fiscal year, and the company's own shares account for 5.48% of the total outstanding shares.
Stocks News Premium = Support for resolving "Drug Loss", marking related Stocks with support for clinical trials of new drugs overseas.
To resolve the 'drug loss' issue, which prevents the use of new drugs approved overseas but not in Japan, the government will support early commercialization through clinical trial assistance. There is a desire to mark related stocks. <M&A is also frequent> In Japan, the time until new drugs are approved is relatively long, and due to issues such as clinical trial costs and profitability, overseas Drug Manufacturers may not aim to enter. Many new drugs in this state of drug loss exist, and patient groups are seeking improvements.
The Nikkei average dropped significantly, down 1,023 yen, with a decrease in the margin as trading came to a close on the 11th in the afternoon session.
On the 11th, the Nikkei Stock Average in the afternoon session sharply fell by 1,023.42 yen from the previous day, closing at 33,585.58 yen. The TOPIX (Tokyo Stock Price Index) also declined by 72.49 points, reaching 2,466.91 points. On the 10th, the U.S. government announced that the tariffs imposed on China would total 145% instead of the previously stated 125%. In response, concerns over the escalation of U.S.-China trade friction heightened, leading to a sharp drop in the U.S. stock market on the 10th, with the Dow Inc and the Nasdaq Composite Index experiencing significant declines. Japanese stocks also plummeted following the sharp drop of U.S. stocks.
The Nikkei average is down about 1,800 yen, continuing to be weak due to the decline in U.S. stocks and the appreciation of the yen = 11 days before the market opened.
On the 11th at around 10:02 AM, the Nikkei average stock price was trading at approximately 32,800 yen, down about 1,800 yen from the previous day. At 9:45 AM, it hit a low of 32,626.58 yen, down 1,982.42 yen. The US administration announced on the 10th that the tariffs imposed on China would cumulatively reach 145%. In response, concerns about the intensification of US-China trade friction have risen again, and on the 10th in the US stock market, the NY Dow and Nasdaq Composite Index experienced a sharp decline. Japanese stocks also faced selling pressure following the sharp drop in US stocks.
Highlighted stock: Expecting expansion of Share, a significant increase in profit is anticipated this term.
Shinnihon Kagaku <2395.T> is expected to expand its Share in the non-clinical fields in which it excels. The stock price is approaching its recent low, and it is believed to demonstrate resistance to selling. The efficacy and safety of drugs are tested using animals and other methods in non-clinical trials. The company is Japan's largest Contract Research Organizations, breeding experimental primates in-house. Regarding non-clinical CROs (Contract Research Organizations), the world's largest, Charles River Group, is undergoing restructuring.
Shin Nippon Biomedical Laboratories JV Aims to Bring Painless Blood Collection Tech to Japan